Zobrazeno 1 - 10
of 778
pro vyhledávání: '"KING TE"'
Autor:
Susan P. Kemp, Hunia Te Urukaiata Mackay (Ngāti Toa Rangatira, Ngāti Koata, Ngāti Rangitihi, R, Michelle Egan-Bitran, Paula Toko King (Te Aupōuri, Te Rarawa, Ngāpuhi, Ngāti Whātua, Waikato, Amanda Smith, Shana Valente, Carmel West, Tupua Urlich, Zak Quor, Jennifer Prapaiporn Thonrithi, Kiri Phillips, Carolyn Phillips, Isaac Heron, Saron Bekele, Stanley Baldwin
Publikováno v:
Journal of the Royal Society of New Zealand. :1-15
Autor:
Seppälä, Ulla, Selby, David, Monsalve, Rafael, King, Te Piao, Ebner, Christof, Roepstorff, Peter, Bohle, Barbara
Publikováno v:
In Molecular Immunology June 2009 46(10):2014-2021
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, 1988 Feb 01. 85(3), 895-899.
Externí odkaz:
https://www.jstor.org/stable/31360
Publikováno v:
In Protein Expression and Purification August 1999 16(3):410-416
Autor:
Durheim, MT, Collard, HR, Roberts, RS, Brown, KK, Flaherty, KR, King, TE, Palmer, SM, Raghu, G, Snyder, LD, Anstrom, KJ, Martínez, FJT
Publikováno v:
Durheim, MT; Collard, HR; Roberts, RS; Brown, KK; Flaherty, KR; King, TE; et al.(2015). Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: Analysis of a pooled cohort from three clinical trials. The Lancet Respiratory Medicine. doi: 10.1016/S2213-2600(15)00093-4. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/7nx273p7
© 2015 Elsevier Ltd. Background: Mortality is an impractical primary endpoint for clinical trials in patients with idiopathic pulmonary fibrosis who have mild-to-moderate physiological impairment because event rates are low. Change in forced vital c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::f779ea12ee5065f8d815706fa0930f57
http://www.escholarship.org/uc/item/7nx273p7
http://www.escholarship.org/uc/item/7nx273p7
Autor:
Assayag, D, Vittinghoff, E, Ryerson, CHRISTOPHER J, Cocconcelli, Elisabetta, Tonelli, Roberto, Elicker, B, Golden, J, Jones, Kd, King, Te, Koth, Ll, Lee, JOYCE SUJIN, Ley, B, Wolters, Pj, Collard, Hr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3674::3738795f9abdbe9b80cd0b1dde65cdb9
https://hdl.handle.net/11380/1146703
https://hdl.handle.net/11380/1146703
Autor:
Ballantyne, KN, Ralf, A, Aboukhalid, R, Achakzai, NM, Anjos, MJ, Ayub, Q, Balažic, J, Ballantyne, J, Ballard, DJ, Berger, B, Bobillo, C, Bouabdellah, M, Burri, H, Butler, J, Capal, T, Caratti, S, Carracedo, A, Cartault, F, Carvalho, EF, Cheng, B, Coble, MD, Comas, D, Corach, D, D'Amato, ME, Davison, S, de Carvalho, EF, de Knijff, Peter, de Ungria, M, Decorte, Ronny, Dobosz, T, Dupuy, BM, Elmrghni, S, Gliwinski, M, Gomes, SC, Grol, L, Haas, C, Hanson, E, Henke, J, Hill, CR, Holmlund, G, Honda, K, Immel, U, Inoue, S, Jobling, MA, Kaddura, M, Kim, JS, Kim, SH, Kim, W, King, TE, Klausriegler, E, Kling, D, Kovacevic, LL, Kovatsi, L, Krajewski, P, Kravchenko, S, Larmuseau, Maarten, Lee, EY, Lee, SH, Lessig, R, Livshits, LA, Marjanovic, D, Minarik, M, Mizuno, N, Moreira, H, Morling, N, Mukherjee, M, Nagaraju, J, Neuhuber, F, Nie, S, Nilasitsataporn, P, Nishi, T, Oh, HH, Olofsson, J, Onofri, V, Palo, JU, Pamjav, H, Parson, W, Payet, C, Petlach, M, Phillips, C, Ploski, R, Prasad, SPR, Primorac, D, Purnnomo, GA, Purps, J, Rangel, H, Rebala, K, Rerkamnuaychoke, B, Rey, D, Robino, C, Rodríguez, F, Roewer, L, Rosa, A, Sajantila, A, Sala, A, Salvador, J, Sanz, P, Schmitt, C, Sharma, AK, Silva, DA, Shin, KJ, Sijen, T, Sirker, M, Siváková, D, Skaro, V, Solano-Matamoros, C, Souto, L, Stenzl, V, Sudoyo, H, Syndercombe-Court, D, Tagliabracci, A, Taylor, D, Tillmar, A, Tsybovsky, IS, Tyler-Smith, C, van der Gaag, K, Vanek, D, Völgyi, A, Ward, D, Willemse, P, Winkler, C, Yap, EPH, Yong, RYY, Zupanic Pajnic, I, Kayser, M
Relevant for various areas of human genetics, Y-chromosomal short tandem repeats (Y-STRs) are commonly used for testing close paternal relationships among individuals and populations, and for male lineage identification. However, even the widely used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1131::c4091677ebcae6f67f205a17be48b75d
https://lirias.kuleuven.be/handle/123456789/454527
https://lirias.kuleuven.be/handle/123456789/454527
Autor:
King, Talmadge, Valeyre, D, Albera, C, Bradford, WZ, Costabel, U, King, TE, Leff, JA, Noble, PW, Sahn, SA, du, RM
Publikováno v:
King, Talmadge; Valeyre, D; Albera, C; Bradford, WZ; Costabel, U; King, TE; et al.(2014). Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/9322495m
Background and objective: Pirfenidone is an oral antifibrotic agent that is approved in several countries for the treatment of idiopathic pulmonary fibrosis (IPF). We performed a comprehensive analysis of safety across four clinical trials evaluating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::00880c48b1845a8a22167981d08db63e
http://www.escholarship.org/uc/item/9322495m
http://www.escholarship.org/uc/item/9322495m
Autor:
Collard, HR, Yow, E, Richeldi, L, Anstrom, KJ, Glazer, C, Schwarz, M, Zisman, DA, Hunninghake, G, Chapman, J, Olman, M, Lubell, S, Morrison, LD, Steele, MP, Haram, T, Roman, J, Perez, R, Perez, T, Ryu, JH, Utz, JP, Limper, AH, Daniels, CE, Meiras, K, Walsh, S, Brown, KK, Bair, C, Kervitsky, D, Lasky, JA, Ditta, S, De Andrade, J, Thannickal, VJ, Stewart, M, Lynch, J, Calahan, E, Lopez, P, King, TE, Golden, JA, Wolters, PJ, Jeffrey, R, Noth, I, Hogarth, DK, Sandbo, N, Strek, ME, White, SR, Brown, C, Garic, I, Maleckar, S, Martinez, FJ, Flaherty, KR, Han, M, Moore, B, Toews, GB, Dahlgren, D, Raghu, G, Hayes, J, Snyder, M, Loyd, JE, Lancaster, L, Lawson, W, Greer, R, Mason, W, Kaner, RJ, Monroy, V, Wang, M, Lynch, DA, Colby, T, Becker, RC, Eisenstein, EL, MacIntyre, NR, Rochon, J, Sundy, JS, Davidson-Ray, L, Dignacco, P, Edwards, R, Anderson, R, Beci, R, Calvert, S, Cain, K, Gentry-Bumpass, T, Hill, D, Ingham, M, Kagan, E, Kaur, J, Matti, C, McClelland, J, Meredith, A, Nguyen, T, Pesarchick, J, Roberts, RS, Tate, W, Thomas, T, Walker, J, Whelan, D, Winsor, J, Yang, Q, Reynolds, HY
Publikováno v:
Collard, HR; Yow, E; Richeldi, L; Anstrom, KJ; Glazer, C; Schwarz, M; et al.(2013). Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respiratory Research, 14(1). doi: 10.1186/1465-9921-14-73. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/0nx322g5
Background: Acute exacerbation of idiopathic pulmonary fibrosis has become an important outcome measure in clinical trials. This study aimed to explore the concept of suspected acute exacerbation as an outcome measure.Methods: Three investigators ret
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::14122d9d9ffb6124fd3848b1cde317b6
http://www.escholarship.org/uc/item/0nx322g5
http://www.escholarship.org/uc/item/0nx322g5
Autor:
King TE Jr, Albera, C, Bradford, Wz, Costabel, U, Hormel, P, Lancaster, L, Noble, Pw, Sahn, Sa, Szwarcberg, J, Thomeer, M, Valeyre, D, du Bois RM, INSPIRE Study Group, Agostini, Carlo, Allen, J, Anzueto, A, Behr, J, Bonnet, R, Buhl, R, Burge, S, Chan, A, Chan, C, Chanez, P, Chapman, J, Cordier, J, Covelli, H, Crimi, N, de Andrade, J, Delaval, P, Dromer, C, Egan, J, Enelow, R, Ettinger, N, Flaherty, K, Floreani, A, Frankel, S, Frost, A, Gibson, K, Glassberg, M, Gottfried, M, Harari, S, Helmersen, D, Hollingsworth, H, Horton, M, Jennings, J, Kallay, M, Lasky, J, Lee, A, Leonard, C, Lorch, D, Lynch, J, Mageto, Y, Mette, S, Millar, A, Morell Brotad, F, Müller Quernheim, J, Nathan, S, Noth, I, Padilla, M, Poletti, V, Raghu, G, Richeldi, L, Robbins, M, Rolf, J, Roman, J, Rosen, G, Rottoli, P, Saltini, C, Schaberg, T, Schaumberg, T, Scholand, M, Schönfeld, N, Sharma, S, Simonelli, P, Steele, M, Sussman, R, Tino, G, Vogelmeier, C, Wallaert, B, Wells, A, Wencel, M, Wesselius, L, Whelan, T, Wilcox, P, Wolters, P, Xaubet, A, Zisman, D.
Publikováno v:
Lancet (London, England). 374(9685)
Summary Background Idiopathic pulmonary fibrosis is a fatal disease for which no effective treatment exists. We assessed whether treatment with interferon gamma-1b improved survival compared with placebo in patients with idiopathic pulmonary fibrosis